TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Minimum Masking Level (MML)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum-tolerated dose of elimusertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects who can choose a dialysis modality
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of subjects that choose a form of home dialysis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of subjects interested in kidney transplant
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fracture pattern following BSSO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condylar segment position following BSSO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Health Impact Profile-14 (OHIP-14)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum observed concentration (Cmax) for vepdegestrant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from time zero to extrapolated infinite time [AUC (0 - ∞)] for vepdegestrant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal observed plasma concentration (Cmax) of eptinezumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic clearance (CL) of eptinezumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of biological therapy for cardiac arrhythmia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Times needed for spontaneous eye opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Experience Measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incentive Salience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Administration
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Diagnostic sensitivity of Dynamic Ultrasonography assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic specificity of Dynamic Ultrasonography assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor necrosis factor alpha (TNFα)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Transforming growth factor beta (TGFβ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to 12 hours (AUC0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Incidence of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Concentrated attention test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patient-reported outcome measures (PROM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Golden time for intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity of headpulse measurements to detect concussion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Problems Index II
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Volatile organic compounds in end stage liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volatile organic compounds in end stage kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volatile organic compounds after liver transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intake of intact cooked whole grains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of cerebral small vessel disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Aortic pulse wave velocity (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Mean Peak Oxygen Consumption (VO2 Peak) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1C less than 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gestational weight gain before OGTT screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Area under curve (AUC) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 0-10 Numerical Rating Scale of Pain change score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 0-10 Numerical Rating Scale of Pain (Pain Relief following Practice Sessions)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 0-10 Numerical Rating Scale of Pain (Weekly average pain intensity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Countermovement Jump (CMJ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International index of erectile function (IIEF)
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Change in Working Memory Performance - Letter-number Span Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Working Memory Performance - Spatial Span Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence and severity of treatment related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinicohematological responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Patients Who Died
Endpoint domain: Mortality/survival
Primary endpoint: Ulnar and Radial Artery Diameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: venous puncture pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in body composition (muscle mass and skeletal mass index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasmatic levels of Klotho
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Clinical COPD Questionnaire (CCQ) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants experiencing at least one adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with discontinuations due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically significant changes in vital signs as a measure of safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak tiotropium concentration in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero to 30 minutes (AUC30 minutes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero to 72 hours (AUC72 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anxiety as measured by the Multidimensional Anxiety Scale for Children (MASC-2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of subjects achieving weight restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in EORTC-QLQ C30 Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in lung density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent of participants with disease relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum urate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of abnormal clinical laboratory
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mean Low-density lipoprotein cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Staff perspectives on delivering day-case endourology surgery
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: MRI outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PSA outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Re-biopsy outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Grade of delayed gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of patients with cancer cell/macrophage hybrid cells in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neuropathic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma EBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: icu admission / reintubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: postoperative pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Positive Agreement (Sensitivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Percent Agreement (Specificity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of blood lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical success at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of successful recited poems reported by independent observers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in happiness reported objectively by independent observers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Count of Participants With a Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Count of Participants With a Response to Treatment at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of pertussis among COPD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Correlation between pertussis and COPD exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Generic Children's Health-Related Quality of Life Questionnaire (KINDL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Universal Goniometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder Pain and Functional Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Breast cancer risk assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in urinary oxalate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Modified Ashworth Scale (MAS) for tone of the Primary Target Muscle Group (PTMG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical Global Impression of Change (CGI-C) Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gait variability (immediate effect of stimulation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait variability (no stimulation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macrophage quantification status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain Score Before Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Score During Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Score After Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability in upper-limb
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hand diagrams
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microenvironment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended dose for phase II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Modified Rivermead Mobility Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Subjective Happiness Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Dark Adaptation recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in drusen volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Strength measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of postoperative delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: frequency of postoperative cognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in dental inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stabilization of the periodontal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay to surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ORR after neoadjuvant SBRT+Tislelizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pathologic response rate on evaluation of the resected specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AUCt of CKD-349, D113
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CKD-349, D113
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cranial Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Numeric Rating Scale (NRS-11)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Centrality of Pain Scale (COPS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Pain Beliefs Questionnaire (PBQ)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Compliance With Independent Training of Skills
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: tumor disease control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of CTCAE grade 3 toxic reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of CTCAE grade 4 and 5 toxic reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Change in esport performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative abundance of Akkermansia muciniphila in gut
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The change of waist circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The change of body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of pathogenic genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of cataracts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the amplitude of the Reward Positivity (RewP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the amplitude of the Late Positive Potential (LPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of TEAEs related to elinzanetant
Endpoint domain: Adverse events/effects
Primary endpoint: Change of minimal erythema dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Antibody seroconversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: self-efficacy related to healthy diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-efficacy related to protection from substance abuse
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-efficacy related to sexuality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-efficacy related to check-up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-efficacy related to accidents and injuries
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life Of Multiple Sclerosis Patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Composite Language Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Motor Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Cognitive Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with adverse events considered related to treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Peak oxygen consumption (VO2) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the proportion of peanut specific Th2a+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the proportion of activated peanut specific T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Event rate of lipohypertrophy
Endpoint domain: Adverse events/effects
Primary endpoint: Temperatures of face, torso and legs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late gastrointestinal and genito-urinary toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Annualized Bleeding Rate (ABR) for Treated Bleeds and All Bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Dose (IU/kg) of Associated Treatment Received for Bleeding Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in monthly countable motor seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of persisting new or uncontrolled arterial hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of a combined hypertensive complication endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of a combined hypotensive complication endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in mean level of acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in mean level of digital working alliance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neutralizing antibodies against ZIKA virus (ZIKV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Isokinetic Muscle Strength Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Dynamic balance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death from any cause or hemodynamic collapse or recurrent PE
Endpoint domain: Mortality/survival
Primary endpoint: Change on Assessment of Living with Aphasia
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change on PI-adapted version of Pet Partners Animal-handler Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Early reperfusion of the residual intracranial occlusion(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Late reperfusion of the residual intracranial occlusion(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Reversal of Hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Non-displaceable binding potential (BPND) of 11C-UCB-J
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in synaptic density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positivity to HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of patients who decide to enroll in clinical trial
Endpoint domain: Resource use
Endpoint subdomain: Other resource use